New findings in restenosis described by O. Iida and co-researchers

According to a study from Amagasaki, Japan, "Although in clinical practice endovascular therapy (EVT) with I nitinol stent for femoro-popliteal artery (FPA) lesions has been widely applied for TASC II A/B lesions. primary patency beyond 2 years remains Unknown. as do (lie factors associated with restenosis Methods and Results: A prospectively maintained database that included 189 limbs treated with nitinol stents for de novo TASC II A/B FPA lesions was retrospectively analyzed The outcomes were overall primary and secondary patency during the follow-up period and predictors associated with restenosis. Primary patency overall with nitinol stents %/;its 84%. 82%, 80%. 80% and i;econdary...

Want to see the full article?

• Purchase this article for only $3.00